| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
|
Medicine details |
|
| Medicine name | panitumumab (Vectibix®) |
| Formulation | 20 mg/ml concentrate for solution for infusion |
| Reference number | 547 |
| Indication | Treatment of patients with wild-type KRAS metastatic colorectal cancer, first-line in combination with FOLFOX, or second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/08/2011 |
| NICE guidance | TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |